Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dynamic changes in sRAGE levels and relationship with cardiac function in STEMI patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Influence of sample centrifugation on plasma platelet count and activated partial thromboplastin time using patient samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Uncarboxylated Matrix Gla-Protein: A Biomarker of Vitamin K Status and Cardiovascular Risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Duration of early systolic lengthening: prognostic potential in the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: Soluble receptor of advanced glycation end-products (sRAGE) may be a predictive biomarker in coronary artery disease (CAD). Patients with acute myocardial infarction (AMI) have higher sRAGE levels compared to healthy subjects. Accordingly, the aim of this study was to investigate the dynamic changes in sRAGE levels during AMI and relationship with cardiac dysfunction.

DESIGN AND METHODS: We prospectively included 80 patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). sRAGE concentrations were measured before pPCI, immediately after pPCI and again on the first and second following days. Left ventricular ejection fraction (LVEF) was evaluated 1-3 days after the pPCI and again at a median of 7months by echocardiography, and infarct size was measured by cardiac magnetic resonance.

RESULTS: sRAGE levels were high in the early phase of AMI; sRAGE levels significantly increased after pPCI compared with sRAGE before pPCI (median ratio: 1.25, 95% CI: 1.15-1.35, P<0.001), and the increase was observed prior to Troponin I (TnI). sRAGE levels decreased notably the first day after pPCI (median ratio: 0.34, 95% CI: 0.30-0.39, P<0.001). Peak sRAGE independently associated with long-term cardiac dysfunction estimated by LVEF (P=0.008). Furthermore, sRAGE measured after pPCI associated with infarct size (P=0.038).

CONCLUSIONS: sRAGE levels were high in the early phase rather than in the days after AMI and pPCI. The increase in sRAGE was seen before detectable changes in TnI. In addition, sRAGE was independently associated with long-term cardiac dysfunction.

OriginalsprogEngelsk
TidsskriftClinical Biochemistry
Vol/bind48
Udgave nummer4-5
Sider (fra-til)297-301
Antal sider5
ISSN0009-9120
DOI
StatusUdgivet - mar. 2015

ID: 45315802